Can 'Good' cholesterol predict COVID-19 survival?

NCT ID NCT05113836

Completed Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study looks at how lipoproteins, like HDL (good cholesterol) and LDL (bad cholesterol), change in patients with severe COVID-19 in the intensive care unit. Researchers will measure specific proteins on these particles to see if they can predict which patients are at higher risk of dying. The goal is to better understand the body's response to the virus and potentially identify new ways to assess disease severity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Deep nasopharyngeal swab and blood samples for lipid analysis
What this could lead to: If successful, this could lead to a new prognostic marker to identify high-risk COVID-19 patients and potentially guide future therapies that boost HDL function.
What could go wrong: This is an observational study, so it cannot prove cause and effect. The findings may not apply to all patients or lead to direct treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV2 INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-COV2 INFECTION

Contacts and locations

Locations

Hôpital Bichat

Paris, 75018, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.